Altered T-Cell Function in Schizophrenia: A Cellular Model to Investigate Molecular Disease Mechanisms by Craddock, Rachel M. et al.
Altered T-Cell Function in Schizophrenia: A Cellular
Model to Investigate Molecular Disease Mechanisms
Rachel M. Craddock
1, Helen E. Lockstone
1, David A. Rider
2, Matthew T. Wayland
1, Laura J. W. Harris
1, Peter J. McKenna
3, Sabine Bahn
1*
1Institute of Biotechnology, University of Cambridge, Cambridge, United Kingdom, 2Institute of Molecular and Cell Biology, Proteos, Singapore,
3Fulbourn Hospital, Cambridge, United Kingdom
Despite decades of research into the aetiology and pathophysiology of schizophrenia, our understanding of this devastating
disorder remains incomplete, with adverse consequences for both diagnosis and treatment. Here we investigate whether
differences between patients and controls can be observed in peripheral patient tissue, with a view of establishing a means for
dynamic investigations into cell function. In vitro stimulation of peripheral blood CD3+ pan T cells with anti-CD3 (clone OKT3)
was used to investigate disease-associated cell responses. T cells from both medicated (n=39), unmedicated (n=6) and
minimally medicated (n=5) schizophrenia patients were found to have significantly lower proliferative responses to
stimulation, compared to well-matched controls (n=32). Expression of CD3 and TCR (T cell receptor) ab chains was equivalent
between patients and controls, ensuring equal stimulation with anti-CD3, and there was no significant difference in the
proportions of CD4+ and CD8+ T cells between samples (n=12). Lower T cell proliferation in schizophrenia patients was not
found to result from deficient early tyrosine phosphorylation signalling or lower IL-2 (interleukin-2) production, as these
parameters were similar between patients and controls, as was the expression of CD25, the IL-2 receptor a chain. Analysis of
CD45 isoforms, however, revealed that patients had a significantly greater percentage of CD8+ and CD4+ CD45RA+ cells before
stimulation and significantly higher fluorescence intensity of CD45RA on CD4+ and CD8+ cells before and after stimulation.
There was significantly higher expression of CD45 RB on both CD4+ and CD8+ unstimulated cells, with a trend towards lower
numbers of CD45RO+ T cells in patient blood. Gene expression analysis in freshly isolated T cells from six minimally treated or
first onset patients and six controls was carried out using human whole-genome CodeLink microarrays to identify functional
pathways that may affect the ability of patient cells to respond to stimulation. Functional profiling showed prominent
transcript changes in categories pertaining to cell cycle machinery, intracellular signalling, oxidative stress and metabolism.
Intriguingly, chromosomal location analysis of genes significantly altered between schizophrenia and controls revealed
clusters at 1p36, 1q42 and 6p22, which have previously been identified as strong susceptibility loci for schizophrenia.
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Investigate Molecular Disease Mechanisms. PLoS ONE 2(8): e692. doi:10.1371/journal.pone.0000692
INTRODUCTION
Effective diagnosis and treatment of schizophrenia remains an
enormous problem for patients and clinicians while the aetiology
of the disorder and the underlying pathophysiological mechanisms
are not fully understood. The very nature of this disorder makes it
difficult to find suitable research tools and accessible tissues for
experimentation, especially as it remains unclear whether
pathological differences in schizophrenia can be detected outside
the brain. Many studies carried out to date have focused on
human post mortem brain tissue and unfortunately, problems
including drug treatment and post mortem effects can impede the
acquisition of high quality data, masking important disease-related
changes. The key aim of the current study was therefore to
establish a suitable surrogate cell system, free from the influence of
post mortem artefact, in which to investigate dynamic functional
investigations of disease-associated pathophysiological mechanisms
as well as the identification of schizophrenia biomarkers, whilst
limiting problems such as drug effects.
In the present study, peripheral blood T cells were utilised to
perform dynamic investigations into cell function using in vitro
stimulation. T cells are a promising candidate for investigations
into cellular function as in vitro stimulation allows for thorough
examination of a variety of key cellular mechanisms, including
intracellular signalling and gene transcription. This system makes
it possible to identify any subtle deficiencies in systemic cell
function which may underpin some of the clinical characteristics of
this disorder. Stimulation of T cells can be carried out in vitro by
mimicking a T cell receptor (TCR) signal via cross-linking of cell
surface CD3, using a monoclonal antibody. This ultimately results
in cell cycle entry and production of cytokines, particularly IL-2
which is used by T cells in an autocrine fashion to drive
proliferation. There is also up regulation of various activation
markers, including CD25, which is the specific a-chain subunit of
IL-2, facilitating T cell responses to this cytokine. As T cell
activation requires receptor signalling, transcription factor activa-
tion, gene transcription, protein synthesis and protein trafficking,
systemic abnormalities in these physiological processes in schizo-
phrenia can potentially be traced in this model by using
downstream effects of stimulation such as proliferation, cytokine
production and gene transcription as readouts of cell function.
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Sample collection
Peripheral blood was taken from well characterised medicated
schizophrenia patients who met DSM-IV criteria for a diagnosis of
schizophrenia, and minimally medicated patients with a confirmed
diagnosis of schizophrenia who had either received less than
4 weeks of therapy, or who were non-compliant with drug
therapy. Blood was also taken from unmedicated patients with
first episode psychosis, who presented with clinical symptoms
consistent with a diagnosis of schizophrenia (DSM-IV). Addition-
ally, the majority of patients in this study were assessed by
a standardised interview (SCID) and the Positive and Negative
Symptoms Scale (PANSS). For each patient sample, blood was
taken from corresponding age, sex, and race matched controls.
Controls were also matched as far as possible for smoking. Patients
and controls were excluded from the study if they had any co-
morbidity such as diabetes, heart disease, thyroid disease,
autoimmune disease or any recent infections and patients with
a history of substance abuse were excluded. All patient samples
were processed concomitantly with their respective controls (see
patient demographics, Table 1). Written consent was obtained
from subjects in line with Cambridgeshire Local Ethics Committee
approval.
T cell isolation
CD3+ T cells were isolated from the peripheral blood of
schizophrenia patients and age, sex and race-matched controls.
In brief, peripheral blood was taken using the S-monovette blood
collection system containing EDTA (Sarstedt). Mononuclear cells
(PBMC) were isolated by centrifugation over Ficoll-Paque
(Amersham Biosciences, Amersham, UK) and CD3+ pan T cells
were then purified from these by negative selection using MACS
human pan T cell isolation kit with LS separation columns
(Miltenyi Biotech, UK). T cell purity was routinely above 98%,
when analysed for CD3-e expression by flow cytometry (FACS
Calibur, Becton Dickinson). Where indicated, cells were cultured
at 37uC in RPMI medium containing 10% foetal bovine serum
and 1% penicillin, streptomycin and glutamine (Sigma, UK).
T cell proliferation
Proliferative responses to stimulation were measured using
3H-
thymidine incorporation into progeny cell DNA. T cells were
cultured for 48 hours in 96 well plates coated with 0 mg/ml,
0.01 mg/ml, 0.1 mg/ml and 1 mg/ml anti-CD3 (clone OKT3),
seeded at a density of 2610
5 cells / well to stimulate entry into the
cellcycle. Cells were pulsed with of0.037MBq (1 mCi)
3H-thymidine
(Amersham Biosciences, UK) per well for a further24 hours to allow
incorporation into DNA and harvested onto 96 well filter plates
(Perkin Elmer) to capture labelled DNA. Labelled DNA and hence
proliferation was measured using a scintillation counter (Top Count,
Packard). All conditions were carried out in triplicate and statistical
significance was determined using a non-parametric Mann-Whitney
U test, with a p-value of less than 0.05 considered significant.
Analysis of cell surface markers by flow cytometry
Patient and control T cells were cultured for 72 hours in the
presence or absence of 1 mg/ml plate-bound anti-CD3. Cells were
counted and 5610
5 cells/sample were washed in FACS buffer
(PBS, 2% foetal bovine serum, Sigma, UK), resuspended and
stained in 100 ml FACS buffer (PBS, 2% foetal calf serum, Sigma,
UK) containing either anti-CD3 Cy5 (Dako, Denmark)/anti-CD4
FITC (BD Biosciences, Pharmingen, UK)/anti-CD8 PE (Bios-
ciences, Pharmingen, UK), anti-CD4 PE (Biosciences, Pharmin-
gen, UK)/anti-CD25FITC (Immunotech, France), anti-CD4 PE/
anti-CD45RA FITC (Serotec, UK), anti-CD4 PE/ anti-CD45RB
FITC (Serotec, UK), anti-CD45RO PE (Serotec, UK) or anti-
CD4 FITC/anti-TCRab PE (Biosciences, Pharmingen, UK).
Cells were incubated at 4uC for 20 minutes before further washing
in FACS buffer. Cells were counted using FACS Calibur and Cell
Quest software (BD Biosciences, UK). Data were analysed using
Flowjo (Treestar, USA). In brief, lymphocytes were gated using
forward scatter and side scatter parameter as an indication of cell
size and granularity in order to exclude non-cellular debris. The
lymphocyte population was analysed according to CD4 and CD8
expression and each parameter was measured separately on CD4+
populations and CD8+ populations. Significance was determined
using the Mann-Whitney U Test.
Table 1. Demographic details of patients and controls
..................................................................................................................................................
Proliferation Medicated Minimally medicated Microarrays Flow cytometry
Control Patient Control Patient Control Patient Control Patient
Age 34610.5 35610.8 2966.9 28610.4 3066.4 31614.1 3167.3 33.2614.3
Sex Male 21 35 10 9 3 2 9 9
Female 11 4 2 2 3 4 7 4
Race White 26 35 7 7 6 6 16 13
Black 1 3 1 1 - - - -
Asian 4 1 4 3 - - - -
Oriental 1 - - - - - - -
Smoking Smoker 12 20 2 4 2 4 7 6
Non-Smoker 15 7 10 5 4 2 9 7
Not known 5 12 - 2 - - - -
Age, sex and race matched controls were compared to medicated schizophrenia patients and a set of minimally medicated and unmedicated schizophrenia patients for
proliferation assays. T cells from minimally medicated and unmedicated patients were also used to assess differential gene expression by microarray and for flow
cytometric analysis of cell surface marker expression. Ages are expressed as mean 6 standard deviation. Patients with recent substance abuse were excluded from the
study.
doi:10.1371/journal.pone.0000692.t001
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plex cytokine detection system
T cells were cultured at a density of 0.2610
5 cells/well for
48 hours in 96 well plates cultured with 0 mg/ml, 0.01 mg/ml,
0.1 mg/ml and 1 mg/ml anti-CD3 clone OKT3. Supernatants
were carefully transferred to microfuge tubes, centrifuged to
remove contaminating cells and stored at 280uC until use.
Production of IL-2 was measured in T cell supernatants using
BeadlyteH human 22-plex cytokine detection system (Upstate,
USA), following manufacturers protocol and results were read on
a LuminexH 100
TM system (Biorad, UK).
Microarray analysis of T cell gene expression
Differential gene expression between T cells from six minimally
treated schizophrenia patients and six age, sex and race matched
controls was investigated using CodeLink
TM Human Whole
Genome Bioarrays (GE Healthcare, UK). Total RNA was
extracted from freshly isolated T cells using QIAamp RNA blood
mini kit (Qiagen, UK) and quality was assessed with a high-
resolution electrophoresis system (Agilent Technologies, Palo Alto,
CA, USA). Biotin-labelled cRNA was generated from each sample
following the manufacturer’s protocol. cRNA was hybridised onto
CodeLink whole genome microarray slides, washed and hybri-
dised cRNA species were detected using Cy5-Streptavidin
(Ameraham, UK). Slides were scanned using GenePix Personal
4100A Microarray Scanner (Axon Instruments) and analysed with
CodeLink Expression Analysis software.
Preprocessing and normalization of microarray data
Probes were initially filtered to include only those with signal
above background noise level, using the strict criterion that probes
must be flagged ‘good’ by the CodeLink software on all chips in
the experiment. This reduced the number of probes included in
the analysis from 53485 to 12416. The spot mean signal intensities
for these probes were read into the R statistical program (http://
www.r-project.org/) for further analysis, using Bioconductor [1]
packages where appropriate. Data were normalised using the
quantile method [2] and quality control (QC) procedures were
performed to identify potential outlier chips. These included
analysis of pairwise correlations of normalised expression values
for all chips, boxplots of the normalised expression values for each
chip and comparing each chip to a pseudo-median chip. With
these QC steps, any chip showing a markedly different profile to
others in the experiment can be visually identified; however, there
are no defined criteria to help decide whether a chip should be
classed as an outlier and excluded. In this study, all chips showed
very comparable profiles and hence the final analysis was
conducted on 6 schizophrenia and 6 control samples.
Detection of differentially expressed genes in
freshly-isolated T-cells
Schizophrenia patient and control samples were paired according to
demographic variables as well as collection and processing of the
samples. Paired t-tests between patients (n=6) and controls (n=6)
wereperformedusingtheLimma(linearmodelsformicroarraydata)
package to identify differential expression [3]. A correction for
multipletesting wasapplied with the ‘qvalue’package[4] and probes
with q,0.05 were considered differentially expressed.
Pathway Analysis
Onto-Express [5, 6] was used to perform functional profiling of the
genes significantly altered in freshly-isolated T-cells from schizo-
phrenia patients compared to controls. This analysis identifies gene
ontology (GO) categories that are over-represented in the list of
significant probes relative to the representation on the array.
Significant probe IDs were mapped to corresponding Entrez IDs
using Onto-Translate [6] and submitted to Onto-Express. Default
settings were used and the reference array was the Amersham
CodeLink human whole genome. Biological process categories with
a corrected p,0.05 and containing more than 2 genes were selected
as the most important pathways affected in the disease state.
Chromosomal mapping
Chromosomal mapping and analysis was performed using an in-
house algorithm (see supplementary information for details). This
method was designed for use with Affymetrix data and so CodeLink
probe IDs were first mapped to Affymetrix probe-set IDs using
Onto-Translate [6]. The main steps in the analysis are outlined
below: (i) a representative probe-set for each gene was selected, using
alignment score information provided by Affymetrix (www.affyme-
trix.com). The representative probe-sets were then mapped to their
alignment region and discarded if this did not correspond to the
chromosomal location of the target gene; (ii) a sliding window of
length 5 MB was used to assess the distribution of differentially
expressed genes across the genome; (iii) each window was assigned
a score, based on the binomial distribution, with high scores
corresponding to regions that contain an excess of differentially
expressed genes; (iv) based on the scores, chromosomal regions
containing a high proportion of differentially expressed genes, which
may have some biological significance, were identified.
RESULTS
Proliferative responses to stimulation with anti-CD3
are significantly lower in patients with
schizophrenia.
3H-thymidine incorporation was used to measure the proliferation of
peripheral blood T cells from 39 medicated schizophrenia patients
and 32 controls (Figure 1A), stimulated with 0 mg/ml, 0.01 mg/ml,
0.1 mg/ml and 1 mg/ml anti-CD3. Medicated patients with
schizophrenia were found to have significantly lower responses to
stimulation at all concentrations of anti-CD3 (0.01 mg/ml anti-CD3
p=0.0007, 0.1 mg/ml anti-CD3 p=0.001, 1 mg/ml anti-CD3
p=0.001) when analysed using non-parametric Mann-Whitney
Ut e s t .
In order to exclude the possibility that lower proliferative
responses were a drug effect, changes in unmedicated and mini-
mally medicated individuals were also examined (Figure 1B).
3H-
thymidine incorporation was measured in 11 minimally and
unmedicated patients and 12 matched controls with significantly
lower proliferative responses to stimulation with anti-CD3 at
concentrations of 0.1 mg/ml (p=0.034) and 1 mg/ml (p=0.034).
Proportions of CD4+ and CD8+ T cells are similar
between patients and controls
As CD3+ pan T cells were isolated and used for all experiments, it
was necessary to measure the proportions of CD4+ and CD8+ T
cells within these populations, as differences in these may also affect
proliferation and also make the samples more heterogeneous.
There were no significant differences in the numbers of CD4+
and CD8+ T cells between patient and control samples (Figure 2).
Importantly, there was also no significant difference in the
percentages of CD4+ and CD8+ cells following stimulation,
suggesting that each of these cell subtypes were proliferating
proportionally within samples. Populations of CD4+ and CD8+
T Cells in Schizophrenia
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TCRab, CD25 and CD45 isoforms.
Lower proliferative responses in schizophrenia T
cells are not a result of lower CD3 or TCR ab
expression
Having observed a lower response to stimulation with anti-CD3 in
both treated and untreated patients, we investigated whether this
was due to lower surface expression of this molecule on
schizophrenia patient T cells. CD3 expression was measured in T
cells from patients and controls before and after stimulation using an
antibody against CD3e, conjugated to Cy5 (Figure 3A). There was
no significant difference in the expression of CD3 on T cells
between patients and controls both in unstimulated cells and in
those treated with anti-CD3, indicating that the lower proliferative
responses of patients were not a result of lower CD3 expression.
Similarly, expression of TCRab was compared between patients
and controls before and after stimulation (figure 3B). The TCR is
down regulated following stimulation as a means of modulating
responses and can affect rates of proliferation following stimulation.
Patients and controls had comparable levels of TCRab in both
unstimulated and OKT3-stimulated samples, where the TCR was
down regulated to a similar degree.
Lower proliferative responses in patient T cells is not
a result of lower IL-2 production or lower expression
of the IL-2 receptor CD25
Following stimulation, T cells produce and use IL-2 in an
autocrine fashion which is required to drive proliferation [7]. As
production and response to this cytokine can both greatly
influence rates of proliferation, IL-2 production was compared
between patients and controls. IL-2 production was measured in
supernatants from OKT3-stimulated and unstimulated T cell
samples using a BeadlyteH human 22-plex cytokine detection
system. There was no significant difference in the production of
IL-2 by patient and control T cells stimulated with plate-bound
anti-CD3 at concentrations of 0 mg/ml, 0.01 mg/ml, 0.1 mg/ml
and 1 mg/ml (figure 4A), demonstrating that insufficient IL-2
production is not responsible for lower T cell proliferative
responses observed in schizophrenia patients.
Expression of CD25 (the IL-2 receptor alpha chain) on CD4+
and CD8+ T cells was also investigated using flow cytometry to
investigate whether patient T cells are unable to respond to IL-2 as
efficiently as healthy controls. CD25 can also be used as a marker
for T cell activation as it is not generally expressed on
unstimulated cells, but is up regulated in response to stimulation
[8]. There was no significant difference in the percentage of cells
expressing CD25 before or after stimulation in patients compared
to controls (Figure 4B), demonstrating that patient cells are able to
up regulate expression of this receptor, allowing them to respond
to IL-2. Similarly, the level of expression of CD25 on patient and
control cells before and after stimulation were comparable
(Figure 4C).
Schizophrenia patients have higher numbers of
circulating CD45RA+ and CD45RB+ T cells
CD45 is a transmembrane protein tyrosine phosphatase that plays
an essential role in early activation of tyrosine kinases necessary for
TCR signal transduction. It is composed of large heavily
Figure 1. Patients with schizophrenia show lower proliferative responses to stimulation with anti-CD3. (A) Medicated schizophrenia patients were
found to have significantly lower proliferative responses to in vitro stimulation compared to healthy controls at all concentrations of stimulation with
anti-CD3. (B) T cell proliferation was also measured in minimally medicated and unmedicated patients to rule out the possibility of drug effect. These
also showed significantly lower proliferative responses to stimulation.
doi:10.1371/journal.pone.0000692.g001
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different isoforms due to the process of alternative RNA splicing of
the extracellular domains [9]. The expression of combinations of
extracellular domains results in the isoforms CD45RA, CD45RB,
CD45RC and CD45RO, which can be identified using specific
monoclonal antibodies. Differential expression of these isoforms
can be used as an estimation of T cell activation state from antigen
exposure [10]. Naı ¨ve cells express the high molecular weight
CD45RA and activated and memory cells express the low
molecular weight CD45RO [11]. CD45RB is expressed on
intermediates as cells differentiate into memory cells.
Expression of CD45RA, CD45RB and CD45RO isoforms was
measured on T cells before and after stimulation in order to assess
differences in T cell sub-populations between patients and
controls. CD45RA was expressed on a significantly higher
percentage of patient CD4 and CD8 T cells before stimulation
(figure 5A: % CD45RA+ unstimulated CD4 cells p=0.038, %
CD45RA+ unstimulated CD8 cells p=0.008) and expression
intensity, proportional to the amount of receptor expressed on the
cell, was significantly higher in patient CD4 and CD8 cells both
before and after stimulation (Figure 5B: Fluorescence intensity
CD45RA before stimulation on CD4+ cells p=0.049 and after
stimulation p=0.024, fluorescence intensity of CD45RA on CD8
cells before stimulation p=0.004 and after stimulation p = 0.018).
CD45RB was expressed on 100% of patient and control cells
before and after stimulation (data not shown) and expression
intensity was found to be significantly higher on CD4 and CD8
patient cells before stimulation (Figure 5C: Fluorescence intensity
of CD45RB before stimulation on CD4+ cells p=0.004 and on
CD8+ cells p=0.022 ).
The percentage of CD45RO+ patient and control T cells was
also measured before and after stimulation and although
differences were not significant, there was a trend towards lower
numbers of CD45RO+ patient T cells (Figure 5D).
Analysis of differentially expressed genes in freshly
isolated T cells from schizophrenia patients and
matched controls
T cell proliferative responses to stimulation with anti-CD3 can be
influenced by many factors. The processes involved in T cell
activationincludecellsignalling,genetranscription,proteinsynthesis
and trafficking, entry into cell cycle and cytokine secretion. Dys-
functioninanyofthesemayresultinthe observed lowerproliferative
responses of patients. Preliminary studies were initially conducted to
investigate early signalling, 5 minutes after T cell stimulation with
anti-CD3. This was carried out by Western blot analysis on T cell
lysates using an antibody raised against global phospho-tyrosine. No
differences were evident in the patterns of tyrosine phosphorylation
between patients and controls (data not shown), suggesting that
deficits responsible for the lower proliferative responses lie further
downstream of events following T cell stimulation.
We employed CodeLink
TM Human Whole Genome micro-
arrays to profile gene expression in peripheral blood T cells from
unmedicated and minimally medicated patients (n=6) and
controls (n=6), in order to identify altered gene expression that
could underlie lower proliferative responses in patients. Paired t-
tests were then used to identify significantly differentially expressed
genes, resulting in 399 probes significant at q,0.05 after multiple
testing correction. Of these, 320 (80%) probes were decreased in
schizophrenia and 79 were increased.
Functional profiling of significantly altered
transcripts
OntoExpress [5, 6] was used to assign functional categories to the
significantly altered genes and to identify processes that were over-
represented in the list of significant genes. This analysis revealed
five significant categories pertaining to cell cycle, including cell
Figure 2. Proportions of CD4+ and CD8+ T cells are similar in schizophrenia patients compared to controls. Expression of CD4 and CD8 was
measured on CD3+ T cells from minimally medicated and unmedicated patients and controls. There was no significant difference in proportions of
CD4 and CD8 T cells between patients and controls either before of after stimulation, suggesting that there is not preferential expansion of either of
these populations following stimulation.
doi:10.1371/journal.pone.0000692.g002
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of cell cycle (p=0.001), mitosis (p=0.005) and regulation of cell
cycle (p=0.039) (Table 2). These categories each contained
a combination of up- and down regulated transcripts. It is
intriguing that categories pertaining to cell cycle were significantly
altered in freshly isolated, unstimulated T cells in light of the lower
proliferative responses to stimulation with anti-CD3 observed in
patients.
Four categories relating to intracellular signalling were also
significantly different between patients and controls. Abnormalities
with signalling pathways potentially hold considerable conse-
quences for proliferative responses to anti-CD3. The four path-
ways pertaining to cell signalling were signal transduction
(p=0.0009), cell-cell signalling (p=0.012), protein amino acid
phosphorylation (p=0.015) and intracellular signalling cascade
(p=0.050).
Other categories that were revealed as significantly altered by
OntoExpress included response to oxidative stress (p=0.0003),
electron transport (p=0.001) and metabolism (p=0.013).
Chromosomal location of significantly altered
transcripts
In order to further investigate the differences in gene expression
between schizophrenia patients and controls, a heat map was
generated, visualising the chromosomal locations of differentially
expressed genes. Clusters of genes significantly altered between
patients and controls from freshly isolated T-cells were identified
at chromosomal regions 1p36, 1q42, 4q12, 6p22, 9q22, 10q26
(Figure 6). Although no clear candidate genes were identified in
these regions, it is of note that 1p36, 1q42 and 6p22 are strong
susceptibility loci for schizophrenia (OMIM).
DISCUSSION
The aim of the present study was to identify physiological
differences between schizophrenia patients and healthy controls in
peripheral tissue, with the hope of establishing a functionally
representative tissue alternative to the brain in which to study
pathophysiological mechanisms associated with this disorder.
Figure 3. Patient and control T cells show similar levels of CD3 and TCRab expression before and after stimulation. (A) CD3 Expression was
measured by flow cytometry on patient and control T cells before and after stimulation with anti-CD3. There was no significant difference in the level
of expression between patients and controls. (B) Expression of TCR ab chains on the surface of T cells was also comparable between patients and
controls before and after stimulation.
doi:10.1371/journal.pone.0000692.g003
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and animal models, and although considerable advances have
been made using these resources, post mortem tissue can never
provide the basis for dynamic functional studies and post mortem
effect and suitable control matching will always be problematic
[12]. Similarly, animal models are associated with major draw-
backs, as until we understand the aetiology of schizophrenia, we
cannot establish truly representative models of psychosis or
Figure 4. Lower T cell proliferation in schizophrenia does not result from deficient IL-2 production, or receptor expression. (A) IL-2 production
was measured in supernatants from patient and control T cells stimulated with 0 mg/ml, 0.01 mg/ml, 0.1 mg/ml and 1 mg/ml OKT3. There was no
significant difference in production of IL-2 between patients and controls at each concentration of OKT3. (B) The percentage of CD25+ CD4+ and
CD8+ T cells was similar between patients and controls before and after stimulation and there was no significant difference in level of expression of
CD25 before or after stimulation (C).
doi:10.1371/journal.pone.0000692.g004
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PLoS ONE | www.plosone.org 7 August 2007 | Issue 8 | e692Figure 5. Schizophrenia patients have higher proportions of circulating CD45RA+ and CD45RB+ T cells. Expression of CD45RA, CD45RB and
CD45RO was measured on CD4+ and CD8+ T cells from patients and controls in order to assess activation state with regard to antigen experience. (A)
The percentage of CD45RA+ cells was significantly higher in patients compared to controls before stimulation and the level of expression of CD45RA
was also higher on patient CD4+ and CD8+ cells before and after stimulation (B). (C) CD45RB expression was significantly higher on CD4+ and CD8+
patient T cells before stimulation. (D) There was no significant difference in the expression of CD45RO on either CD4+ or CD8+ T cells from patient or
control cells.
doi:10.1371/journal.pone.0000692.g005
T Cells in Schizophrenia
PLoS ONE | www.plosone.org 8 August 2007 | Issue 8 | e692schizophrenia. Existing models are, at best, models for hypotheses.
In this study we used peripheral blood T cells as a model system
for dynamic investigations into alterations in cell function with the
hope of eventually relating disease-associated changes to the brain.
Schizophrenia is a clinically heterogeneous disorder with
a spectrum of symptoms. Although the disorder primarily affects
brain function (especially thoughts, affect, perception, social
functioning and cognition), it is unknown whether other organs
are affected. The tissue type and stage of disease when a given
sample was collected are also likely to influence findings. Changes
throughout disease progression could also significantly impede the
identification of consistent pathological changes if patients are
investigated at different stages of their illness. Indeed, physiological
mechanisms triggering positive or negative symptoms in the early
disease stages could differ significantly from chronic illness and
remission. To start to address the complexity of this symptomat-
ically defined disorder, we need to conduct studies aimed at
identifying clear and consistent differences between patients and
controls, ideally identifying accessible tissues in which we can
detect disease-related changes. More extensive longitudinal studies
will then be required to characterise the physiological changes
associated with different disease states.
Our findings of lower T cell proliferative responses to anti-CD3
in schizophrenia add to previous reports of immune alterations in
schizophrenia. These findings are not consistent across all studies,
possibly arising from biological changes throughout the course of
the disorder or reflecting the possibility that schizophrenia
represents a spectrum of clinically related disorders, each with
differing underlying pathologies. One of the most frequently
reported immunological alterations reported in schizophrenia is an
imbalance in T helper 1 (TH1) and T helper 2 (TH2) cytokine
profile production with a skew towards TH2 cytokine profiles in
schizophrenia patients [13, 14], suggested as reflecting diminished
pro-inflammatory TH1 responses in schizophrenia. Lower num-
bers of CD4+ cells and hence IL-2 production have also been
reported in schizophrenia [15], although Muller et al describe
increased CD4+ cell number [16], in addition to altered plasma
and serum levels of other cytokines such as IL-6 [17]. Differing
proportions of leukocyte subsets with higher numbers of CD5+ B
cells [18], higher proportions of naı ¨ve (CD45RA+) T cells [19] and
decreased T suppressor cell activity [16] have all been reported.
There have also been associations between schizophrenia and
autoimmune diseases, with higher levels of autoantibodies detected
in patients, including anti-cardiolipin antibodies, anti-histone,
rheumatoid factor, lupus anticoagulant and antibodies to the
hippocampus and septal region of the brain [20–24]. Kessler and
Shinitzky reported platelet autoantibodies, which have been
shown to inhibit dopamine uptake [25].
In the present study, we observed significantly lower pro-
liferative responses to T cell stimulation with anti-CD3 in
schizophrenia patients compared to controls, demonstrating that
physiological differences can indeed be identified in peripheral
tissues. There are many reasons why patient T cells may respond
poorly to stimulation by proliferation. Cell functional abnormal-
ities such as suboptimal expression of signalling molecules or
genes necessary for cell cycle progression, or abnormalities
with energy supply and utilisation may underlie these effects.
Similarly, cell extrinsic inhibitory factors present within patients’
bodies may diminish proliferative responses. Circulating stress
hormones or products of oxidative stress may alter the ability of
cells to respond, as may chronic T cell activation within the
patients’ bodies.
Table 2. Functional pathways associated with cell cycle, cell signalling and oxidative stress and metabolism were significantly
altered in schizophrenia by microarray analysis of gene expression.
..................................................................................................................................................
CELL CYCLE
GO ID Category Number significant
genes in category
Total number genes
in category
Corrected P-Value
GO:0007049 cell cycle 8 307 4.878E-04
GO:0007050 cell cycle arrest 4 83 7.352E-04
GO:0045786 negative regulation of cell cycle 4 107 1.112E-03
GO:0007067 mitosis 3 106 5.257E-03
GO:0051301 cell division 3 158 1.224E-02
GO:0000074 regulation of cell cycle 3 283 3.859E-02
CELL SIGNALLING
GO:0007242 intracellular signaling cascade 4 451 0.0495
GO:0006468 proteinamino acid phosphorylation 7 628 0.0153
GO:0007267 cell-cell signaling 5 331 0.0116
GO:0007165 signal transduction 18 1503 0.0009
METABOLISM AND OXIDATIVE STRESS
GO:0006979 response to oxidative stress 4 57 2.725E-04
GO:0008152 metabolism 6 481 1.313E-02
GO:0006118 electron transport 8 390 9.889E-04
Onto-Express was used for pathway analysis of significantly altered genes by identifying gene ontology (GO) categories that are over-represented in the list of
significant genes relative to the representation on the array. Five categories associated with cell cycle were found to be significantly involved, including cell cycle
(p=0.0005), cell cycle arrest (p=0.0007), negative regulation of cell cycle (p=0.001), mitosis (p=0.005) and regulation of cell cycle (p = 0.039).
Four categories associated with cell signalling were found to be significantly altered, including signal transduction (p=0.0009), cell-cell signalling (p=0.012), protein
amino acid phosphorylation (p=0.015) and intracellular signalling cascade (p=0.050).
Three categories involved in oxidative stress were found to be significantly altered, including response to oxidative stress (p=0.0003), electron transport (p=0.001) and
metabolism (p=0.013).
doi:10.1371/journal.pone.0000692.t002
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PLoS ONE | www.plosone.org 9 August 2007 | Issue 8 | e692In the present study CD3 and TCRab expression were found to
be comparable on patient and control T cells, demonstrating that
patient cells are capable of responding to in vitro stimulation.
Patient and healthy control T cell samples also had comparable
proportions of CD4+ and CD8+ T cells, altered numbers of which
could result in different rates of proliferation between patients and
controls. These data suggested that there is no obvious receptor
proximal abnormality which could initially prevent patient T cells
from responding similarly to control cells when stimulated with
anti-CD3.
Cell cycle entry marks the culmination of a complex and
intertwined array of cell signals and processes, abnormalities of
any one of which may be responsible for depressed proliferative
responses in patient T cells. Early T cell receptor signalling was
investigated by looking at global tyrosine phosphorylation events
following stimulation. Patient and control T cell lysates were
investigated by Western blot, using an antibody against phospho-
tyrosine. There were no visible differences in the levels of tyrosine
phosphorylation (data not shown), representative of early Src
family tyrosine kinase signalling, in patient and control T cells
following stimulation, suggesting that early signalling pathways in
patients are intact, and do not contribute to lower proliferative
responses. Downstream of early receptor signalling, IL-2 is
produced and used by T cells in an autocrine fashion in response
to stimulation to drive proliferation [7]. As such, any abnormalities
in the production or use of this cytokine could result in lower
proliferative responses. Patients were found to produce similar
amounts of IL-2 to healthy controls at a range of stimulating
concentrations of anti-CD3 (Figure 4A) and expression of CD25,
the specific alpha-chain of the IL-2 receptor was similar between
patients and controls (Figure 4B and 4C), demonstrating that
although patients have lower proliferative responses to anti-CD3,
they are capable of producing and responding to IL-2. CD25 is
also an indicator of activation state, with low expression on
unstimulated cells which increases following stimulation. Expres-
sion and up regulation of CD25 on patient T cells demonstrates
that although these cells are not proliferating as quickly as their
healthy counterparts, patient T cells are capable of becoming
activated and producing the cytokine IL-2 and also suggests that
cell pathways involved in protein trafficking and receptor recycling
are intact, with abnormalities involved in lower proliferative
responses lying downstream of the bifurcation of these pathways.
Figure 6. Genes significantly altered between patient and control T cells map to known schizophrenia susceptibility loci. A heat map was
generated in order to identify the chromosomal location of significantly differentially expressed genes from patient and control T cells. Clusters of
significantly altered genes between SZ and C freshly isolated T-cells were found at 1p36, 1q42, 4q12, 6p22, 9q22, 10q26. 1p36, 1q42 and 6p22 are
strong susceptibility loci
doi:10.1371/journal.pone.0000692.g006
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PLoS ONE | www.plosone.org 10 August 2007 | Issue 8 | e692Expression of CD45 isoforms was measured on patient and
control T cells, both to further investigate availability of T cell
receptor complex components on patient cells and as a means of
assessing differences in antigen experience between patients and
controls. Cazullo et al previously reported increased CD4+ and
CD8+ CD45RA+ T cells in schizophrenia patients, suggesting
higher numbers of antigen naı ¨ve T cells [19]. They suggested that
exogenous factors present in the patients body stimulated
expansion of the CD4+ and CD8+ CD45RA+ populations and
a reduction in numbers of CD45RA- memory cells. Our data
supported these finding as increased expression of CD45RA
andCD45RB was found, together with a trend towards lower
CD45RO expression. These data together could suggest that
schizophrenia patients have higher numbers of naı ¨ve compared to
antigen-experienced memory T cells. It is important to note that
CD45 isoform expression is only a crude estimation of activation
state. Antigen experience has been classified into four denomina-
tions; naı ¨ve cells (CD28+ CD45RA+ CCR7+ CCR62 CD62L+
CD27+ CD11a low) [26, 27], antigen experienced cells
(CD45RO+ CD282 CCR72 CD11a+), central memory cells
(CD45RO+ CD28+ CCR7+ CD11a +) and effecter memory cells
(CD45RO+ CCR72 CD11a+) [28]. More recent evidence shows
that co-expression of a range of markers including CD27, CD28,
CCR5, CCR6, CCR7, CD62L and CD11a alter independently
with progressive cell divisions and differentiation [26, 27, 29]. It has
also been demonstrated that a subset of CD4RA+ CD27+ CD282
T cells areantigen experienced,expanded cloneswhich respond well
to re-stimulation [26]. Further studies are therefore indicated to
analyse the true phenotype and function of expanded CD45RA+ T
cellpopulationsinschizophrenia to determine whetherpatients have
increased numbers of CD45RA+ naı ¨ve T cells, or increased reverted
CD45RA+antigenexperiencedcells.Thisishoweveracomplexand
rapidly progressing field and it is challenging to assign in vivo function
to intricate sub-phenotypes of T cell.
Our finding of increased CD45RA and CD45RB expression on
patient cells clearly suggests that the patient group appear to have
altered populations of antigen experienced T cells. This could be
interpreted in a number of ways. Either comparable numbers of
patient CD45RO+ cells are not generated from CD45RA+ cells at
the same rate as in healthy control cell populations, there may be
higher rates of reversion to CD45RA+ from CD45RO+ following
antigen exposure, or perhaps inadequate survival factors result in
deletion of generated CD45RO+ cells. Alternatively, higher
numbers of CD45RA+ T cells may be generated in patients.
Regarding isoform switching of CD45RA+ naı ¨ve cells to
CD45RO+ memory cells; it is very hard to imagine that
schizophrenia patients are not exposed to the same infections
and antigens as the rest of the general population and therefore
that their CD45RA+ populations do not convert to CD45RO+
memory cells at the same rate. Cellular mechanisms involved in
antigen processing and presentation and T cell responses to
antigen could be less efficient in schizophrenia, reflected by our
findings of lower proliferative responses to anti-CD3 stimulation.
Interestingly, there are various reports in the literature that point
to cellular hyporesponsiveness in schizophrenia. Riedel et al
reported lower type IV delayed skin hypersensitivity reactions in
schizophrenia patients [30], suggesting defects in cell mediated
immune responses with sensitised TH-1 helper T cells and Russo et
al importantly showed significantly lower antibody responses to
vaccination with hepatitis B in psychiatric patients [31]. Together
with a negative correlation of schizophrenia with chronic
inflammatory diseases, such as rheumatoid arthritis [32], these
data could suggest diminished T cell responses in schizophrenia,
although it should be considered that chronic activation of T cells,
as seen in chronic inflammatory diseases such as rheumatoid
arthritis and SLE can result in hyporesponsiveness to in vitro
stimulation [33, 34]. Higher expression of CD45RA in patient
populations could instead indicate higher rates of reversion to
CD45RA from CD45RO.
Despite the many reports of immune alteration in schizophre-
nia, there is a lack of clinical support for specific immune
dysfunction in schizophrenia. Patients are not clinically immuno-
compromised; there are no confirmed reports of opportunistic
infections or a higher incidence of shingles or herpes reactivations,
for example, although the high degree of functional redundancy in
the immune system could prevent clinical immunodeficiency.
To identify deficiencies in any major functional cell pathways
that may provide further evidence of cellular hyporesponsiveness,
we used microarrays to identify candidate genes and pathways that
may be dysregulated in schizophrenia. Functional category
analysis of significantly altered transcripts using OntoExpress
revealed several significantly altered pathways in each of three
functional categories cell cycle, signal transduction and response to
oxidative stress. Each of these processes has previously been
implicated in schizophrenia and may contribute considerably to
lower T cell proliferative responses. Dysregulation of transcripts
involved in cell cycle from freshly isolated T cells are extremely
interesting in light of the observed lower proliferative responses of
patient T cells to stimulation. Transcripts were measured in freshly
isolated unstimulated T cells not in cell cycle, and yet five pathways
associated with cell cycle mechanisms were significantly altered in
schizophrenia, suggesting there may be insufficient constitutive
expression of genes and proteins necessary for normal rates of cell
turnover. Alteration in the expression of genes from cell cycle
categories also carries heavy implications for existing hypotheses of
neurodevelopment and tissue repair, particularly as neural stem cell
proliferation has been found to be decreased in schizophrenia [35].
Abnormalities in expression of genes relating to signal trans-
duction also has huge implications for the pathophysiology of
schizophrenia and its clinical presentation. Intracellular signalling
is one of the most fundamental functions of a cell, crucial for most
cellular processes including energy utilisation, responses to growth
factors and neurotransmitter signalling. We found no deficiencies
in early stimulation-induced tyrosine phosphorylation events in
schizophrenia, however downstream pathways such as MAP
kinase signalling and cytokine signalling may yet be affected. This
certainly requires further investigation, although as signalling
pathways are so complex and intertwined, identifying specific
deficiencies will prove challenging.
Three pathways associated with oxidative stress and metabolism
were also significantly altered in freshly isolated T cells. T cell
responses would obviously be altered by any abnormalities in
energy supply and utilisation, particularly energy dependent
functions such as cell cycle. T cell activation is also particularly
sensitive to the production of reactive oxygen species and oxidative
stress, as many of the upstream signalling phosphatases contain
cysteine residues in their active sites, accounting for lower
proliferative responses in patients. These results were of particular
interest, as these categories were also found to be significantly
altered in schizophrenia in our previous study on prefrontal cortex
of post mortem brains [36], as well as in several peripheral patient
tissues such as liver and red blood cells [37]. In the present study,
members of these functional categories showed a bias towards
down regulation of expression in schizophrenia patient T cells.
Overall 80% of transcripts were down regulated, mirroring
alterations in protein expression from the prefrontal cortex post
mortem brain study, which showed major down regulation of
proteins associated with mitochondria and oxidative stress [36].
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PLoS ONE | www.plosone.org 11 August 2007 | Issue 8 | e692Currently there is insufficient evidence to refute or confirm the
presence of specific immune dysfunction in schizophrenia and it is
still unclear whether immune alterations are reflective of specific
immune dysfunction, are a bystander effect of upstream regulatory
mechanisms, or result from tissue pathology associated with the
disorder. Immune responses are exceedingly dynamic and it is
often hard to demonstrate the presence of an immune response by
looking at one or two isolated aspects of the immune response at
one point in time. Also, physiological inflammation is transient
and may be missed if a population of patients is sampled at one
time point only. Larger immunological studies need to be carried
out, where several parameters can be measured and correlated for
the same individual with follow up tests through different aspects
of the disorder (i.e. prodromal state, psychotic episodes etc.).
The lack of specific immune dysfunction in schizophrenia is
interesting in itself, given the above findings. The immune system
has a high degree of functional redundancy, owing to high
evolutionary pressure from the ‘arms race’ between man and
microbes. It is possible that molecular pathways resulting in lower
proliferative responses and T cell hyporesponsiveness are com-
pensated for in the immune system, for example, by increased
efforts of innate immunity. However the cells responsible for
higher human functions such as cognitive mood may not be able
to compensate for these impairments resulting in the symptoms of
schizophrenia.
Conclusion
Clear and significant physiological differences in T cell responses
can be identified in schizophrenia patients, namely reduced
proliferative responses to stimulation, alterations in T cell
subpopulations expressing CD45 isoforms and expression of genes
associated with cell cycle, cell signalling and oxidative stress and
metabolism. Besides providing an easily accessible cell type in the
living patient, cell biological studies can provide more in depth and
robust results, as dynamic functional studies are possible and
problems resulting from cell and tissue heterogeneity, as
encountered when using post mortem brain homogenates are
not an issue.
There is compelling evidence for cellular dysfunction in
schizophrenia and the mechanisms of this and how it changes
throughout disease progression need to be pinpointed in order to
further our understanding of this disorder.
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